Fiscal Year 2024 Generic Drug Science and Research Initiatives Workshop; Public Workshop; Request for Comments, 9855-9857 [2024-02841]

Download as PDF Federal Register / Vol. 89, No. 29 / Monday, February 12, 2024 / Notices khammond on DSKJM1Z7X2PROD with NOTICES solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2023–D–4974 for ‘‘Advanced Manufacturing Technologies Designation Program.’’ Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit VerDate Sep<11>2014 21:06 Feb 09, 2024 Jkt 262001 both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https:// www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https:// www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500. You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)). Submit written requests for single copies of the draft guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Building, 4th Floor, Silver Spring, MD 20993– 0002; or the Office of Communication, Outreach and Development, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 3128, Silver Spring, MD 20993–0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance document. FOR FURTHER INFORMATION CONTACT: With regard to the draft guidance: Ranjani Prabhakara, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 6648, Silver Spring, MD 20993, 240–402– 4652; or James Myers, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993–0002, 240–402–7911. With regard to the proposed collection of information: Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796– 5733, PRAStaff@fda.hhs.gov. PO 00000 Frm 00022 Fmt 4703 Sfmt 4703 9855 SUPPLEMENTARY INFORMATION: I. Background In the Federal Register of December 13, 2023, FDA published a notice of availability with a 60-day comment period to provide comments on the draft guidance entitled ‘‘Advanced Manufacturing Technologies Designation Program’’ and its proposed collection of information. FDA has received requests to extend the comment period to allow sufficient time to develop and submit meaningful comments. FDA has considered the requests and is extending the comment period for 30 days, until March 13, 2024. The Agency believes that this extension allows adequate time for interested persons to submit comments. II. Electronic Access Persons with access to the internet may obtain an electronic version of the draft guidance at https://www.fda.gov/ drugs/guidance-compliance-regulatoryinformation/guidances-drugs, https:// www.fda.gov/vaccines-blood-biologics/ guidance-compliance-regulatoryinformation-biologics/biologicsguidances, https://www.fda.gov/ regulatory-information/search-fdaguidance-documents, or https:// www.regulations.gov. Dated: February 7, 2024. Lauren K. Roth, Associate Commissioner for Policy. [FR Doc. 2024–02836 Filed 2–9–24; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2023–N–0119] Fiscal Year 2024 Generic Drug Science and Research Initiatives Workshop; Public Workshop; Request for Comments AGENCY: Food and Drug Administration, HHS. Notice of public workshop; request for comments. ACTION: The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop entitled ‘‘FY 2024 Generic Drug Science and Research Initiatives Workshop.’’ The purpose of the public workshop is to provide an overview of the status of science and research initiatives for generic drugs and an opportunity for public input on these initiatives. FDA is seeking this input from a variety of stakeholders— SUMMARY: E:\FR\FM\12FEN1.SGM 12FEN1 9856 Federal Register / Vol. 89, No. 29 / Monday, February 12, 2024 / Notices industry, academia, patient advocates, professional societies, and other interested parties—as it fulfills its commitment under the Generic Drug User Fee Amendments of 2022 (GDUFA III) to develop an annual list of science and research initiatives specific to generic drugs. FDA will take the information it obtains from the public workshop into account in developing its fiscal year (FY) 2025 Generic Drug User Fee Amendments (GDUFA) science and research initiatives. DATES: The public workshop will be held on May 20 and 21, 2024. Either electronic or written comments on this public workshop must be submitted by June 21, 2024. See the SUPPLEMENTARY INFORMATION section for registration date and information. ADDRESSES: The public workshop will be held in person and will be accessible virtually. Registrants will have an opportunity to indicate their interest in attending the public workshop in person. If there are restrictions imposed by applicable health guidelines for inperson gatherings, or seating capacity limitations, registrants interested in attending the public workshop in person will be contacted. The public workshop will be held at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503, sections B and C), Silver Spring, MD 20993–0002. Entrance for the public workshop participants (non-FDA employees) is through Building 1 where routine security check procedures will be performed. For parking and security information, please refer to https:// www.fda.gov/about-fda/visitorinformation. You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of June 21, 2024. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date. khammond on DSKJM1Z7X2PROD with NOTICES Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your VerDate Sep<11>2014 21:06 Feb 09, 2024 Jkt 262001 comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2023–N–0119 for ‘‘FY 2024 Generic Drug Science and Research Initiatives Workshop; Public Workshop; Request for Comments.’’ Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management PO 00000 Frm 00023 Fmt 4703 Sfmt 4703 Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https:// www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https:// www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500. FOR FURTHER INFORMATION CONTACT: Sam Raney, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 4732, Silver Spring, MD 20993, 240–402–7967, Sameersingh.Raney@fda.hhs.gov; or Robert Lionberger, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 4722, Silver Spring, MD 20993, 240–402– 7957, Robert.Lionberger@fda.hhs.gov. SUPPLEMENTARY INFORMATION: I. Background In July 2012, Congress passed the Generic Drug User Fee Amendments of 2012 (GDUFA I) (Pub. L. 112–144). GDUFA I was designed to enhance public access to safe, high-quality generic drugs and to modernize the generic drug program. To support this goal, FDA agreed in the Generic Drug User Fee Act Program Performance Goals and Procedures (GDUFA I commitment letter) to work with industry and interested stakeholders on identifying science and research initiatives specific to generic drugs for each fiscal year covered by GDUFA I. In August 2017, GDUFA was reauthorized until September 2022 through the Generic Drug User Fee Amendments of 2017 (GDUFA II) (Pub. L. 115–52), and in September 2022, GDUFA was reauthorized until September 2027 through the Generic Drug User Fee Amendments of 2022 (GDUFA III) (Pub. L. 117–180, 136 Stat. 2155). In the GDUFA Reauthorization E:\FR\FM\12FEN1.SGM 12FEN1 Federal Register / Vol. 89, No. 29 / Monday, February 12, 2024 / Notices Performance Goals and Program Enhancements Fiscal Years 2023–2027 (GDUFA III commitment letter),1 FDA agreed to conduct annual public workshops ‘‘to solicit input from industry and stakeholders for inclusion in an annual list of GDUFA III regulatory science initiatives.’’ This public workshop scheduled for May 20 and 21, 2024, seeks to fulfill this agreement. II. Topics for Discussion at the Public Workshop The purpose of this public workshop is to obtain input from industry and other interested stakeholders on identifying generic drug science and research initiatives for FY 2025. FDA is interested in receiving input about regulatory science initiatives for the ongoing years of the GDUFA III science and research program, and particularly for FY 2025. Topics discussed during the workshop will focus on research that is needed to address scientific knowledge gaps and associated challenges impacting the development and regulatory assessment of generic products, including complex generics. As examples, topics discussed will likely relate to nitrosamine drug substance-related impurities, drugdevice combination products, predictive tools to improve the efficiency of generic product development, and other topics that can enhance public access to high quality, safe and effective generic products. Specific presentations and discussions at this workshop will be announced at a later date and may differ from the topics above. Input about the topics above will help the Agency identify and expand its scientific focus for the next fiscal year. FDA will consider all comments made at this workshop or received through the docket (see ADDRESSES) as it develops its FY 2025 science and research initiatives. Information concerning the science and research initiatives for generic drugs can be found on the Science & Research website at https:// www.fda.gov/drugs/generic-drugs/ science-research. khammond on DSKJM1Z7X2PROD with NOTICES III. Participating in the Public Workshop Registration: Registration is free. Persons interested in attending this public workshop must register online at https://fda.zoomgov.com/webinar/ register/WN_qwJcEJcWQeeglLe ZMD2MCg. Registration may be 1 The GDUFA III commitment letter is available at https://www.fda.gov/media/153631/download. VerDate Sep<11>2014 21:06 Feb 09, 2024 Jkt 262001 performed at any time before or during the workshop. If you need special accommodations due to a disability, please contact FDA via email at GDUFARegulatoryScience@ fda.hhs.gov no later than 11:59 p.m. eastern time on May 10, 2024. Requests for Oral Presentations: During online registration you may indicate if you wish to present your public comments. Requests to provide public comments via a pre-recorded presentation or a live presentation, including in-person or virtual presentations, should be submitted via email to GDUFARegulatoryScience@ fda.hhs.gov by 11:59 p.m. Eastern Time on March 8, 2024. We will do our best to accommodate requests to make public comments. Individuals and organizations with common interests are urged to consolidate or coordinate their presentations, and request time for a joint presentation, or submit requests for designated representatives to participate in the workshop. Based upon the public comment presentation requests received by March 8, 2024, at 11:59 p.m. eastern time, we will determine the amount of time allotted to each presenter and the approximate time each oral presentation is to begin; we will select and notify participants by April 1, 2024. If selected for presentation, any presentation materials must be emailed to GDUFA RegulatoryScience@fda.hhs.gov no later than May 10, 2024, 11:59 p.m. eastern time. No commercial or promotional material will be permitted to be presented or distributed at the public workshop. Streaming Webcast of the Public Workshop: This public workshop will be webcast. Please register online (as described above) to attend the workshop remotely (virtually). Registrants will receive a hyperlink that provides access to the webcast on both days. Although FDA verified the website addresses in this document, please note that websites are subject to change over time. Transcripts: Please be advised that as soon as a video recording and audio transcript of the public workshop are available, they will be accessible at https://www.regulations.gov or via the Science & Research FDA website accessible at https://www.fda.gov/drugs/ generic-drugs/science-research. They may also be available for viewing at the Dockets Management Staff (see ADDRESSES). Dated: February 6, 2024. Lauren K. Roth, Associate Commissioner for Policy. [FR Doc. 2024–02841 Filed 2–9–24; 8:45 am] BILLING CODE 4164–01–P PO 00000 Frm 00024 Fmt 4703 Sfmt 4703 9857 DEPARTMENT OF HEALTH AND HUMAN SERVICES [Document Identifier: OS–0945–0005] Agency Information Collection Request; 60-Day Public Comment Request Office of the Secretary, HHS. Notice. AGENCY: ACTION: In compliance with the requirement of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, is publishing the following summary of a proposed collection for public comment. DATES: Comments on the ICR must be received on or before April 12, 2024. ADDRESSES: Submit your comments to Sherrette.Funn@hhs.gov, PRA@hhs.gov, or by calling (202) 264–0041. FOR FURTHER INFORMATION CONTACT: When submitting comments or requesting information, please include the document identifier 0945–0005 and project title for reference, to Sherrette A. Funn, email: Sherrette.Funn@hhs.gov, PRA@hhs.gov, or call (202) 264–0041 the Reports Clearance Officer. SUPPLEMENTARY INFORMATION: Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency’s functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden. Title of the Collection: HIPAA Audit Review Survey. Type of Collection: Reinstatement, with Change, of a Previously Approved Collection OMB No. 0945–0005: Office for Civil Rights (OCR)—Health Information Privacy Division. Abstract: This information collection consists of 39 online survey questions that will be sent to 207 covered entities and business associates that participated in the 2016–2017 OCR HIPAA Audits. The survey will gather information relating to the effect of the audits on the audited entities and the entities’ opinions about the audit process. OCR is conducting a review of the 2016–2017 HIPAA Audits to determine its efficacy in assessing the HIPAA compliance efforts of covered entities. SUMMARY: E:\FR\FM\12FEN1.SGM 12FEN1

Agencies

[Federal Register Volume 89, Number 29 (Monday, February 12, 2024)]
[Notices]
[Pages 9855-9857]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-02841]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2023-N-0119]


Fiscal Year 2024 Generic Drug Science and Research Initiatives 
Workshop; Public Workshop; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is 
announcing the following public workshop entitled ``FY 2024 Generic 
Drug Science and Research Initiatives Workshop.'' The purpose of the 
public workshop is to provide an overview of the status of science and 
research initiatives for generic drugs and an opportunity for public 
input on these initiatives. FDA is seeking this input from a variety of 
stakeholders--

[[Page 9856]]

industry, academia, patient advocates, professional societies, and 
other interested parties--as it fulfills its commitment under the 
Generic Drug User Fee Amendments of 2022 (GDUFA III) to develop an 
annual list of science and research initiatives specific to generic 
drugs. FDA will take the information it obtains from the public 
workshop into account in developing its fiscal year (FY) 2025 Generic 
Drug User Fee Amendments (GDUFA) science and research initiatives.

DATES: The public workshop will be held on May 20 and 21, 2024. Either 
electronic or written comments on this public workshop must be 
submitted by June 21, 2024. See the SUPPLEMENTARY INFORMATION section 
for registration date and information.

ADDRESSES: The public workshop will be held in person and will be 
accessible virtually. Registrants will have an opportunity to indicate 
their interest in attending the public workshop in person. If there are 
restrictions imposed by applicable health guidelines for in-person 
gatherings, or seating capacity limitations, registrants interested in 
attending the public workshop in person will be contacted. The public 
workshop will be held at the FDA White Oak Campus, 10903 New Hampshire 
Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503, sections B 
and C), Silver Spring, MD 20993-0002. Entrance for the public workshop 
participants (non-FDA employees) is through Building 1 where routine 
security check procedures will be performed. For parking and security 
information, please refer to https://www.fda.gov/about-fda/visitor-information.
    You may submit comments as follows. Please note that late, untimely 
filed comments will not be considered. The https://www.regulations.gov 
electronic filing system will accept comments until 11:59 p.m. Eastern 
Time at the end of June 21, 2024. Comments received by mail/hand 
delivery/courier (for written/paper submissions) will be considered 
timely if they are received on or before that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2023-N-0119 for ``FY 2024 Generic Drug Science and Research 
Initiatives Workshop; Public Workshop; Request for Comments.'' Received 
comments, those filed in a timely manner (see ADDRESSES), will be 
placed in the docket and, except for those submitted as ``Confidential 
Submissions,'' publicly viewable at https://www.regulations.gov or at 
the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through 
Friday, 240-402-7500.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Dockets Management Staff. If you do not wish 
your name and contact information to be made publicly available, you 
can provide this information on the cover sheet and not in the body of 
your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852, 240-402-7500.

FOR FURTHER INFORMATION CONTACT: Sam Raney, Center for Drug Evaluation 
and Research, Food and Drug Administration, 10903 New Hampshire Ave., 
Bldg. 75, Rm. 4732, Silver Spring, MD 20993, 240-402-7967, 
[email protected]; or Robert Lionberger, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 75, Rm. 4722, Silver Spring, MD 20993, 240-402-
7957, [email protected].

SUPPLEMENTARY INFORMATION: 

I. Background

    In July 2012, Congress passed the Generic Drug User Fee Amendments 
of 2012 (GDUFA I) (Pub. L. 112-144). GDUFA I was designed to enhance 
public access to safe, high-quality generic drugs and to modernize the 
generic drug program. To support this goal, FDA agreed in the Generic 
Drug User Fee Act Program Performance Goals and Procedures (GDUFA I 
commitment letter) to work with industry and interested stakeholders on 
identifying science and research initiatives specific to generic drugs 
for each fiscal year covered by GDUFA I.
    In August 2017, GDUFA was reauthorized until September 2022 through 
the Generic Drug User Fee Amendments of 2017 (GDUFA II) (Pub. L. 115-
52), and in September 2022, GDUFA was reauthorized until September 2027 
through the Generic Drug User Fee Amendments of 2022 (GDUFA III) (Pub. 
L. 117-180, 136 Stat. 2155). In the GDUFA Reauthorization

[[Page 9857]]

Performance Goals and Program Enhancements Fiscal Years 2023-2027 
(GDUFA III commitment letter),\1\ FDA agreed to conduct annual public 
workshops ``to solicit input from industry and stakeholders for 
inclusion in an annual list of GDUFA III regulatory science 
initiatives.'' This public workshop scheduled for May 20 and 21, 2024, 
seeks to fulfill this agreement.
---------------------------------------------------------------------------

    \1\ The GDUFA III commitment letter is available at https://www.fda.gov/media/153631/download.
---------------------------------------------------------------------------

II. Topics for Discussion at the Public Workshop

    The purpose of this public workshop is to obtain input from 
industry and other interested stakeholders on identifying generic drug 
science and research initiatives for FY 2025. FDA is interested in 
receiving input about regulatory science initiatives for the ongoing 
years of the GDUFA III science and research program, and particularly 
for FY 2025.
    Topics discussed during the workshop will focus on research that is 
needed to address scientific knowledge gaps and associated challenges 
impacting the development and regulatory assessment of generic 
products, including complex generics. As examples, topics discussed 
will likely relate to nitrosamine drug substance-related impurities, 
drug-device combination products, predictive tools to improve the 
efficiency of generic product development, and other topics that can 
enhance public access to high quality, safe and effective generic 
products. Specific presentations and discussions at this workshop will 
be announced at a later date and may differ from the topics above. 
Input about the topics above will help the Agency identify and expand 
its scientific focus for the next fiscal year.
    FDA will consider all comments made at this workshop or received 
through the docket (see ADDRESSES) as it develops its FY 2025 science 
and research initiatives. Information concerning the science and 
research initiatives for generic drugs can be found on the Science & 
Research website at https://www.fda.gov/drugs/generic-drugs/science-research.

III. Participating in the Public Workshop

    Registration: Registration is free. Persons interested in attending 
this public workshop must register online at https://fda.zoomgov.com/webinar/register/WN_qwJcEJcWQeeglLeZMD2MCg. Registration may be 
performed at any time before or during the workshop.
    If you need special accommodations due to a disability, please 
contact FDA via email at [email protected] no later 
than 11:59 p.m. eastern time on May 10, 2024.
    Requests for Oral Presentations: During online registration you may 
indicate if you wish to present your public comments. Requests to 
provide public comments via a pre-recorded presentation or a live 
presentation, including in-person or virtual presentations, should be 
submitted via email to [email protected] by 11:59 p.m. 
Eastern Time on March 8, 2024. We will do our best to accommodate 
requests to make public comments. Individuals and organizations with 
common interests are urged to consolidate or coordinate their 
presentations, and request time for a joint presentation, or submit 
requests for designated representatives to participate in the workshop. 
Based upon the public comment presentation requests received by March 
8, 2024, at 11:59 p.m. eastern time, we will determine the amount of 
time allotted to each presenter and the approximate time each oral 
presentation is to begin; we will select and notify participants by 
April 1, 2024. If selected for presentation, any presentation materials 
must be emailed to [email protected] no later than May 
10, 2024, 11:59 p.m. eastern time. No commercial or promotional 
material will be permitted to be presented or distributed at the public 
workshop.
    Streaming Webcast of the Public Workshop: This public workshop will 
be webcast. Please register online (as described above) to attend the 
workshop remotely (virtually). Registrants will receive a hyperlink 
that provides access to the webcast on both days. Although FDA verified 
the website addresses in this document, please note that websites are 
subject to change over time.
    Transcripts: Please be advised that as soon as a video recording 
and audio transcript of the public workshop are available, they will be 
accessible at https://www.regulations.gov or via the Science & Research 
FDA website accessible at https://www.fda.gov/drugs/generic-drugs/science-research. They may also be available for viewing at the Dockets 
Management Staff (see ADDRESSES).

    Dated: February 6, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-02841 Filed 2-9-24; 8:45 am]
BILLING CODE 4164-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.